Rociletinib Active in EGFR-Mutated Non-Small Cell Lung Cancer

Share this content:
Rociletinib was active in patients with EGFR-mutated NSCLC associated with the T790M resistance mutation.
Rociletinib was active in patients with EGFR-mutated NSCLC associated with the T790M resistance mutation.

Rociletinib, an epidermal growth factor receptor (EGFR) inhibitor, was active in patients with EGFR-mutated non-small cell lung cancer (NSCLC) associated with the T790M resistance mutation, a study published in The New England Journal of Medicine has shown.

For the phase I/II study, researchers enrolled 130 patients with EGFR-mutated NSCLC who had disease progression during previous treatment with an existing EGFR inhibitor.

Of those, 57 received the free-base form of rociletinib 150mg once daily to 900mg twice daily, while the remaining patients received the hydrogen bromide salt (HBr) form 500 to 1000mg twice daily in continuous 21-day cycles.

Efficacy results showed that the objective response rate among the 46 evaluable patients with T790M-positive disease was 59% (95% CI: 45-73) and was 29% (95% CI: 8-51) among the 17 patients with T790M-negative disease.

The analysis included patients who received the free-base form at a dose of 900mg twice daily or the HBr form at any dose.

RELATED: Awaiting Biomarker Results May Delay Lung Cancer Treatment Decisions

In regard to safety, the study showed that the only common dose-limiting toxicity was hyperglycemia, but researchers did not identify a maximum tolerated dose.

Resistance to EGFR inhibitors is often mediated by the T790M EGFR mutation, but rociletinib has shown activity inEGFR-mutated NSCLC with or without T790M in preclinical models.

Reference

  1. Sequist LV, Soria J-C, Goldman JW, et al. Rociletinib in EGFR-mutated non-small cell lung cancer. N Engl J Med. 2015; 372:1700-1709.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs